Zevra - ADHS - A Star is born (Seite 3)
eröffnet am 06.09.21 11:06:47 von
neuester Beitrag 29.04.24 23:28:00 von
neuester Beitrag 29.04.24 23:28:00 von
Beiträge: 41
ID: 1.352.190
ID: 1.352.190
Aufrufe heute: 0
Gesamt: 4.204
Gesamt: 4.204
Aktive User: 0
ISIN: US4884452065 · WKN: A2QLX7 · Symbol: 1GDA
4,3000
EUR
+3,37 %
+0,1400 EUR
Letzter Kurs 24.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
09.05.24 · globenewswire  |
08.05.24 · globenewswire |
01.05.24 · globenewswire |
29.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6220 | +108,03 | |
| 2,1100 | +64,33 | |
| 55,50 | +36,03 | |
| 1,7870 | +28,56 | |
| 1,0500 | +23,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -31,17 | |
| 2,6200 | -43,04 | |
| 0,7340 | -45,63 | |
| 1,0200 | -53,64 | |
| 3,7600 | -66,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Pascoe ist ein toller Redner. 
Gestern Abend die Analystenkonferenz bei Canacord:
https://wsw.com/webcast/canaccord76/register.aspx?conf=canac…
Gestern Abend die Analystenkonferenz bei Canacord:
https://wsw.com/webcast/canaccord76/register.aspx?conf=canac…
s.S.22ff - ich muss die beiden wohl immer verwechselt haben 
https://cdn.coverstand.com/53489/753929/c2d948ce63998d43ee70…
https://cdn.coverstand.com/53489/753929/c2d948ce63998d43ee70…
Chart sieht gut aus, fundamental eh blendend.
Werd wohl nochmal nachtanken, um den fortlaufenden Wertverlust des Euro abzufedern. Muss man sich mal vorstellen, jetzt zahlt man 5 EUR die 5$ KMPH - das waren Anfang des Jahres beim Wechselkurs von 1.15 EUR/$ noch 4,35 EUR für 5$
Werd wohl nochmal nachtanken, um den fortlaufenden Wertverlust des Euro abzufedern. Muss man sich mal vorstellen, jetzt zahlt man 5 EUR die 5$ KMPH - das waren Anfang des Jahres beim Wechselkurs von 1.15 EUR/$ noch 4,35 EUR für 5$
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
From Redditors to creditors: Orphazyme's wild ride ends with $13M sale to satisfy bankruptcy court
"Orphazyme’s vertiginous decline is over. Having briefly commanded a market cap of $2.7 billion in June 2021, the Danish meme stock is now selling substantially all of its assets and business activities to KemPharm for $12.8 million in cash.
Last summer, day traders, spurred by chatter on Reddit, piled into Orphazyme ahead of an FDA decision about whether to approve its heat shock response amplifier arimoclomol in a rare lysosomal disorder. The activity dragged Orphazyme from relative obscurity, but the decline was as rapid as the rise, with the stock going from $5 to $77 and back down to $15 even before the FDA rejected the therapy..."
https://www.fiercebiotech.com/biotech/redditors-creditors-or…
"Orphazyme’s vertiginous decline is over. Having briefly commanded a market cap of $2.7 billion in June 2021, the Danish meme stock is now selling substantially all of its assets and business activities to KemPharm for $12.8 million in cash.
Last summer, day traders, spurred by chatter on Reddit, piled into Orphazyme ahead of an FDA decision about whether to approve its heat shock response amplifier arimoclomol in a rare lysosomal disorder. The activity dragged Orphazyme from relative obscurity, but the decline was as rapid as the rise, with the stock going from $5 to $77 and back down to $15 even before the FDA rejected the therapy..."
https://www.fiercebiotech.com/biotech/redditors-creditors-or…
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
...
Under the terms of the agreement, KemPharm will purchase substantially all of the assets and operations of Orphazyme, including arimoclomol, for a cash payment of USD $12.8 million. The Company expects to finance the cash payment with a revolving line of credit secured by KemPharm’s balance sheet. KemPharm intends to retain the majority of Orphazyme’s current employees.
...
https://finance.yahoo.com/news/kempharm-announces-strategic-…
ORPHAZYME A/S UNDER IN-COURT-RESTRUCTURING TO SELL SUBSTANTIALLY ALL OF ITS ASSETS AND BUSINESS ACTIVITIES TO KEMPHARM, INC.
May 15, 2022 at 5:00 PM EDT
www.orphazyme.com
ORPH aktuell 0.24$ - vor gut einem Jahr gingen Stücke zu 77$ um
...
Under the terms of the agreement, KemPharm will purchase substantially all of the assets and operations of Orphazyme, including arimoclomol, for a cash payment of USD $12.8 million. The Company expects to finance the cash payment with a revolving line of credit secured by KemPharm’s balance sheet. KemPharm intends to retain the majority of Orphazyme’s current employees.
...
https://finance.yahoo.com/news/kempharm-announces-strategic-…
ORPHAZYME A/S UNDER IN-COURT-RESTRUCTURING TO SELL SUBSTANTIALLY ALL OF ITS ASSETS AND BUSINESS ACTIVITIES TO KEMPHARM, INC.
May 15, 2022 at 5:00 PM EDT
www.orphazyme.com
ORPH aktuell 0.24$ - vor gut einem Jahr gingen Stücke zu 77$ um
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Trading Spotlight
DoctorAcula
Bullish
10:23 AM
$KMPH
Insurance coverage is key!
UnitedHealthcare is the largest health insurance company in the U.S.
AZSTARYS WILL BE COVERED BY THE LARGEST HEALTH INSURANCE COMPANY IN THE US!!!
https://stocktwits.com/DoctorAcula/message/446995201
Bullish
10:23 AM
$KMPH
Insurance coverage is key!
UnitedHealthcare is the largest health insurance company in the U.S.
AZSTARYS WILL BE COVERED BY THE LARGEST HEALTH INSURANCE COMPANY IN THE US!!!
https://stocktwits.com/DoctorAcula/message/446995201
The KemPharm Story, as told by CEO and Co-Founder Travis Mickle.
Event: Cantor Global Healthcare Conference
Date: September 28, 2021
https://investors.kempharm.com/static-files/e19e6c26-f699-49…
Event: Cantor Global Healthcare Conference
Date: September 28, 2021
https://investors.kempharm.com/static-files/e19e6c26-f699-49…
Neues Video, Travis mit verwegenem Bart
Danke Corey und diese "Rechnung" beinhaltet erstmal nur Azstarys - SDX, die 450Mio US$ an Milestone Zahlungen und die 130Mio US$ Cash bei 300Mio MK (schuldenfrei) und der heutige China Kracher bleiben hierbei erstmal außen vor.
"Okay, let’s do some math.
Let’s assume KemPharm can eventually capture 10% of the $18 billion ADHD drug market. That’s $1.8 billion in revenue. If they get an average 15% royalty, ignoring the $450 million in milestone payments, that’s $270 million in gross profit. Assuming the milestone payments cover the fixed expenses, with 35 million shares outstanding, that’s EPS of $7.70.
With a 15-20 multiplier, that’s a share price of $115-155"
https://finance.yahoo.com/quote/KMPH/community?p=KMPH
"Okay, let’s do some math.
Let’s assume KemPharm can eventually capture 10% of the $18 billion ADHD drug market. That’s $1.8 billion in revenue. If they get an average 15% royalty, ignoring the $450 million in milestone payments, that’s $270 million in gross profit. Assuming the milestone payments cover the fixed expenses, with 35 million shares outstanding, that’s EPS of $7.70.
With a 15-20 multiplier, that’s a share price of $115-155"
https://finance.yahoo.com/quote/KMPH/community?p=KMPH
Es wird spannend in 2022
Unser ADHS Medikament jetzt auch für den chinesischen Markt
Leider wird KemPharm nicht erwähnt, aber so ist das halt wenn ein Produkt zum Vertrieb auslizensiert wurde, aber das schälert die News keinesfalls. Sollte die Tage auch noch was Offizielles von KemPharm dazu kommen
Ark Biopharmaceutical Enters Into Exclusive License Agreement for Novel ADHD Treatment Azstarys® in Greater China
December 28, 2021 19:00 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.
AZSTARYS, approved and commercialized by Corium, Inc. in the U.S., is an innovative treatment for ADHD patients ages 6 years and older providing rapid and extended duration symptom control as the First and Only Product containing Prodrug of Dexmethylphenidate
Agreement provides up to a total of $105.5 million USD in upfront, developmental and sales milestone payments, as well as royalties on product net sales
https://www.globenewswire.com/news-release/2021/12/29/235861…
Unser ADHS Medikament jetzt auch für den chinesischen Markt
Leider wird KemPharm nicht erwähnt, aber so ist das halt wenn ein Produkt zum Vertrieb auslizensiert wurde, aber das schälert die News keinesfalls. Sollte die Tage auch noch was Offizielles von KemPharm dazu kommen
Ark Biopharmaceutical Enters Into Exclusive License Agreement for Novel ADHD Treatment Azstarys® in Greater China
December 28, 2021 19:00 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.
AZSTARYS, approved and commercialized by Corium, Inc. in the U.S., is an innovative treatment for ADHD patients ages 6 years and older providing rapid and extended duration symptom control as the First and Only Product containing Prodrug of Dexmethylphenidate
Agreement provides up to a total of $105.5 million USD in upfront, developmental and sales milestone payments, as well as royalties on product net sales
https://www.globenewswire.com/news-release/2021/12/29/235861…
Durchsuchen
Zevra - ADHS - A Star is born
